In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth-Ayerst's Strategic Retreat

Executive Summary

Premarin was the drug that would never die. With its patent long-since expired, Wyeth-Ayerst has nonetheless taken advantage of osteoporosis and other studies to promote the hormone-based drug to more than $800 million in worldwide sales. Now it’s co-promoting what my be its own worst enemy, Merck’s Fosamax. It could thereby profit from this important new drug and, by putting together a disease management program that incorporates both drugs, make an ally out of this competitor. Included is a chart of the industry's osteoporosis deals.

You may also be interested in...



Virus-Hit Astellas Cuts Forecast

Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.

QUOTED. 5 August 2020. Eric Fanning.

AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.

Warp Speed Lives Up To Its Name: FDA Planning Late October Vaccine Advisory Committee

Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.

Topics

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel